Pim J van Leeuwen

The Netherlands Cancer Institute

Papers

1

Total Citations

10

H-Index

1

About

Dr. Pim J. van Leeuwen is a leading urologic oncologist whose research centers on improving the staging and treatment of prostate cancer, with a particular focus on the clinical integration of advanced molecular imaging. His most impactful work investigates the utility of prostate-specific membrane antigen (PSMA) PET/CT in guiding surgical decision-making. In a landmark 2024 study, Dr. van Leeuwen demonstrated that patients undergoing PSMA PET/CT staging prior to radical prostatectomy and extended pelvic lymph node dissection experienced significantly improved early oncological outcomes compared to those staged with conventional imaging. This finding, which has already garnered 10 citations, provides critical evidence for the adoption of PSMA-based imaging as a standard of care. Beyond this core contribution, Dr. van Leeuwen is recognized for his expertise in salvage lymph node dissection and the management of biochemical recurrence. His research directly bridges the gap between diagnostic innovation and surgical precision, offering tangible benefits for patients with high-risk and recurrent prostate cancer. Through his work, Dr. van Leeuwen continues to shape the future of personalized, image-guided prostate cancer surgery.

Research Focus

Key Achievements

1
H-Index
1
Papers
10
Total Citations
10
Avg Citations/Paper
🏆 Most Cited Paper
Early Oncological Outcomes in Patients who Underwent Staging Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Compared with Conventional Imaging Before Radical Prostatectomy and Extended Pelvic Lymph Node Dissection
10 citations · 2024
📈 Most Prolific Year: 2024 (1 Papers)
🤝 Key Collaborators: 12
🏛 Institutions: The Netherlands Cancer Institute

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago